Navin Suthahar1, Laura M G Meems2, Dirk J van Veldhuisen2, Joan E Walter3, Ron T Gansevoort4, Stephane Heymans5, Blanche Schroen5, Pim van der Harst2, Jenny E Kootstra-Ros6, Vanessa van Empel5, Christian Mueller3, Stephan J L Bakker4, Rudolf A de Boer2. 1. University of Groningen, University Medical Center Groningen, Department of Cardiology, the Netherlands. Electronic address: n.suthahar@umcg.nl. 2. University of Groningen, University Medical Center Groningen, Department of Cardiology, the Netherlands. 3. Department of Cardiology, Cardiovascular Research Institute Basel, University Hospital Basel, Switzerland. 4. University of Groningen, University Medical Center Groningen, Division of Nephrology, Department of Internal Medicine, the Netherlands. 5. Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, the Netherlands. 6. University of Groningen, University Medical Center Groningen, Department of Laboratory Medicine, the Netherlands.
Abstract
OBJECTIVE: To evaluate associations of high-sensitivity cardiac troponin-T (cTnT) with cardiovascular disease (CVD), heart failure (HF), and mortality in community-dwelling women and men. PARTICIPANTS AND METHODS: A total of 8226 adults from the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort (1997-1998) were enrolled in a prospective observational study (mean age: 49 years; 50.2% women). Sex-specific associations of cTnT levels with future clinical outcomes were evaluated using adjusted Cox-regression models. RESULTS: Measurable cTnT levels (≥3 ng/L) were detected in 1102 women (26.7%) and in 2396 men (58.5%). Baseline cTnT levels were associated with a greater risk of developing CVD in women than men [Hazard ratio (HRwomen), 1.48 per unit increase in log2-cTnT; 95% CI, 1.21 to 1.81 vs HRmen, 1.20; 95% CI, 1.07 to 1.35; Pinteraction<.001]. Similar sex-related differences were observed for HF (Pinteraction= .005) and mortality (Pinteraction= .008). Further, compared with referent category (cTnT <3 ng/L), women with cTnT levels greater than or equal to 6 ng/L had a significantly increased risk for CVD (HR, 2.30; 95% CI, 1.45 to 3.64), HF (HR, 2.86; 95% CI, 1.41 to 5.80), and mortality (HR, 2.65; 95% CI, 1.52 to 4.61), whereas men with cTnT levels greater than or equal to 6 ng/L had a significantly increased risk only for CVD (HR, 1.51; 95% CI, 1.07 to 2.13). CONCLUSION: Baseline cTnT levels were associated with future CVD, HF, and mortality in both sexes, and these associations were stronger in women. Future studies are needed to determine the value of cTnT in early diagnosis of CVD, particularly in women.
OBJECTIVE: To evaluate associations of high-sensitivity cardiac troponin-T (cTnT) with cardiovascular disease (CVD), heart failure (HF), and mortality in community-dwelling women and men. PARTICIPANTS AND METHODS: A total of 8226 adults from the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort (1997-1998) were enrolled in a prospective observational study (mean age: 49 years; 50.2% women). Sex-specific associations of cTnT levels with future clinical outcomes were evaluated using adjusted Cox-regression models. RESULTS: Measurable cTnT levels (≥3 ng/L) were detected in 1102 women (26.7%) and in 2396 men (58.5%). Baseline cTnT levels were associated with a greater risk of developing CVD in women than men [Hazard ratio (HRwomen), 1.48 per unit increase in log2-cTnT; 95% CI, 1.21 to 1.81 vs HRmen, 1.20; 95% CI, 1.07 to 1.35; Pinteraction<.001]. Similar sex-related differences were observed for HF (Pinteraction= .005) and mortality (Pinteraction= .008). Further, compared with referent category (cTnT <3 ng/L), women with cTnT levels greater than or equal to 6 ng/L had a significantly increased risk for CVD (HR, 2.30; 95% CI, 1.45 to 3.64), HF (HR, 2.86; 95% CI, 1.41 to 5.80), and mortality (HR, 2.65; 95% CI, 1.52 to 4.61), whereas men with cTnT levels greater than or equal to 6 ng/L had a significantly increased risk only for CVD (HR, 1.51; 95% CI, 1.07 to 2.13). CONCLUSION: Baseline cTnT levels were associated with future CVD, HF, and mortality in both sexes, and these associations were stronger in women. Future studies are needed to determine the value of cTnT in early diagnosis of CVD, particularly in women.
Authors: Navin Suthahar; Laura M G Meems; Dion Groothof; Stephan J L Bakker; Ron T Gansevoort; Dirk J van Veldhuisen; Rudolf A de Boer Journal: Eur J Heart Fail Date: 2021-02-08 Impact factor: 15.534
Authors: Navin Suthahar; Laura M G Meems; Coenraad Withaar; Thomas M Gorter; Lyanne M Kieneker; Ron T Gansevoort; Stephan J L Bakker; Dirk J van Veldhuisen; Rudolf A de Boer Journal: Sci Rep Date: 2022-01-07 Impact factor: 4.379
Authors: Victor W Zwartkruis; Bastiaan Geelhoed; Navin Suthahar; Stephan J L Bakker; Ron T Gansevoort; Isabelle C van Gelder; Rudolf A de Boer; Michiel Rienstra Journal: Open Heart Date: 2021-12
Authors: Just Dronkers; Laura M G Meems; Dirk J van Veldhuisen; Sven Meyer; Lyanne M Kieneker; Ron T Gansevoort; Stephan J L Bakker; Michiel Rienstra; Rudolf A de Boer; Navin Suthahar Journal: Eur Heart J Open Date: 2022-03-14
Authors: Valentina Bracun; Navin Suthahar; Canxia Shi; Sanne de Wit; Wouter C Meijers; IJsbrand T Klip; Rudolf A de Boer; Joseph Pierre Aboumsallem Journal: Front Cardiovasc Med Date: 2021-12-08